Edgewise Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Edgewise Therapeutics

07/05/2024 17:33

* Edgewise Therapeutics Inc  EWTX.OQ   EWTX.O  is expected
to show
no change in quarterly revenue when it reports  results on May 9
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Edgewise Therapeutics
Inc is
for a loss of 39 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Edgewise
Therapeutics Inc is $29.00​, above​ its last closing price
of $20.34. ​​​

This summary was machine generated May 7 at 16:33 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)